Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome

Nature Communications

Volumn 6, Issue , 2015, Pages

  Day, Felix R ^a   Hinds, David A ^b   Tung, Joyce Y ^b   Stolk, Lisette ^c   Styrkarsdottir, Unnur ^d   Saxena, Richa ^e   Bjonnes, Andrew ^e   Broer, Linda ^c   Dunger, David B ^a   Halldorsson, Bjarni V ^d,f   Lawlor, Debbie A ^g   Laval, Guillaume ^h   Mathieson, Iain ⁱ   McCardle, Wendy L ^g   Louwers, Yvonne ^j   Meun, Cindy ^j   Ring, Susan ^g   Scott, Robert A ^a   Sulem, Patrick ^d   Uitterlinden, André G ^c   Wareham, Nicholas J ^a   Thorsteinsdottir, Unnur ^d,k   Welt, Corrine ^l   Stefansson, Kari ^d,k   Laven, Joop S E ^j   Ong, Ken K ^a   Perry, John R B ^a   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b 23andMe Inc ^*  (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d DECODE GENETICS   (Iceland)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f REYKJAVIK UNIVERSITY   (Iceland)

^g UNIVERSITY OF BRISTOL   (United Kingdom)

^h INSTITUT PASTEUR   (France)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j GENERAL ELECTRIC COMPANY   (United States)

^k UNIVERSITY OF ICELAND   (Iceland)

^l UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MUELLERIAN INHIBITING FACTOR; RAD50 PROTEIN; SEX HORMONE BINDING GLOBULIN; TRANSCRIPTION FACTOR YAP1; DNA BINDING PROTEIN; DNA LIGASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLLITROPIN BETA SUBUNIT; PHOSPHOPROTEIN; RAD50 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; THADA PROTEIN, HUMAN; TUMOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANCESTRY; ETIOLOGY; GENE EXPRESSION; GENOME; GROWTH RESPONSE; HORMONE; REPRODUCTIVE DISORDER; SERUM; SEX HORMONE;

ADOLESCENT; ALLELE; ARTICLE; BALANCING SELECTION; BODY MASS; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; FOLLOW UP; FSHB GENE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSULIN RESISTANCE; KRR1 GENE; MAJOR CLINICAL STUDY; MENDELIAN RANDOMIZATION ANALYSIS; MENOPAUSE; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; STATISTICAL SIGNIFICANCE; THADA GENE; AGING; CASE CONTROL STUDY; CAUCASIAN; GENETIC SELECTION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; OVARY; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGING; CASE-CONTROL STUDIES; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLICLE STIMULATING HORMONE, BETA SUBUNIT; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NEOPLASM PROTEINS; OVARY; PHOSPHOPROTEINS; POLYCYSTIC OVARY SYNDROME; RECEPTOR, EPIDERMAL GROWTH FACTOR; SELECTION, GENETIC;

EID: 84942749132     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9464     Document Type: Article

References (46)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41-47 (2004).
2. Zawadzki, J. & Dunaif, A. in Polycystic Ovary Syndrome (eds Dunaif, A. G. J. & Haseltine, F.) 377-384 (Blackwell Scientific, 1992).
3. Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum. Reprod. 27, 14-24 (2012).
4. Corbett, S. & Morin-Papunen, L. The polycystic ovary syndrome and recent human evolution. Mol. Cell. Endocrinol. 373, 39-50 (2013).
5. Domecq, J. P. et al. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-Analysis. J. Clin. Endocrinol. Metab. 98, 4655-4663 (2013).
6. Moran, L. J., Hutchison, S. K., Norman, R. J. & Teede, H. J. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst. Rev. CD007506 (2011).
7. Dunaif, A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18, 774-800 (1997).
8. Wild, R. A. et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95, 2038-2049 (2010).
9. Legro, R. S. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 98, 4565-4592 (2013).
10. Barber, T. M. & Franks, S. Genetics of polycystic ovary syndrome. Front. Horm. Res. 40, 28-39 (2013).
11. Chen, Z. J. et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat. Genet. 43, 55-59 (2011).
12. Shi, Y. et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat. Genet. 44, 1020-1025 (2012).
13. Goodarzi, M. O. et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J. Med. Genet. 49, 90-95 (2012).
14. Welt, C. K. et al. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J. Clin. Endocrinol. Metab. 97, E1342-E1347 (2012).
15. Mutharasan, P. et al. Evidence for chromosome 2p16.3 polycystic ovary syndrome susceptibility locus in affected women of European ancestry. J. Clin. Endocrinol. Metab. 98, E185-E190 (2013).
16. Louwers, Y. V., Stolk, L., Uitterlinden, A. G. & Laven, J. S. Cross-ethnic metaanalysis of genetic variants for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 98, E2006-E2012 (2013).
17. Saxena, R. et al. Han Chinese polycystic ovary syndrome risk variants in women of European ancestry: relationship to FSH levels and glucose tolerance. Hum. Reprod. 30, 1454-1459 (2015).
18. Abbott, D. H., Dumesic, D. A. & Franks, S. Developmental origin of polycystic ovary syndrome -A hypothesis. J. Endocrinol. 174, 1-5 (2002).
19. Escobar-Morreale, H. F., Luque-Ramirez, M. & San Millan, J. L. The moleculargenetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr. Rev. 26, 251-282 (2005).
20. Mulders, A. G. et al. Changes in anti-Mullerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum. Reprod. 19, 2036-2042 (2004).
21. Burgess, S., Butterworth, A., Malarstig, A. & Thompson, S. G. Use of Mendelian randomisation to assess potential benefit of clinical intervention. BMJ 345, e7325 (2012).
22. Stolk, L. et al. Meta-Analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat. Genet. 44, 260-268 (2012).
23. Tang, T., Lord, J. M., Norman, R. J., Yasmin, E. & Balen, A. H. Insulinsensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev. 5, CD003053 (2012).
24. Moran, L. J. et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J. Acad. Nutr. Diet. 113, 520-545 (2013).
25. Scott, R. A. et al. Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independently of obesity. Diabetes 63, 4378-4387 (2014).
26. Ding, E. L. et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N. Engl. J. Med. 361, 1152-1163 (2009).
27. Daan, N. M. et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil. Steril. 102, 1444-1451 (2014).
28. Costello, M., Shrestha, B., Eden, J., Sjoblom, P. & Johnson, N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst. Rev. CD005552 (2007).
29. Ciardiello, F. & Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174 (2008).
30. Park, J. Y. et al. EGF-like growth factors as mediators of LH action in the ovulatory follicle. Science 303, 682-684 (2004).
31. Jamnongjit, M., Gill, A. & Hammes, S. R. Epidermal growth factor receptor signaling is required for normal ovarian steroidogenesis and oocyte maturation. Proc. Natl Acad. Sci. USA 102, 16257-16262 (2005).
32. Sheng, Q. & Liu, J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br. J. Cancer 104, 1241-1245 (2011).
33. Davies, S. et al. High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. Int. J. Gynecol. Pathol. 33, 402-410 (2014).
34. Hurtado, A. et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456, 663-666 (2008).
35. Chen, D. J. et al. Two follicle-stimulating hormone receptor polymorphisms and polycystic ovary syndrome risk: a meta-Analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 182C, 27-32 (2014).
36. Mason, H. & Franks, S. Local control of ovarian steroidogenesis. Baillieres Clin. Obstet. Gynaecol. 11, 261-279 (1997).
37. Burt Solorzano, C. M. et al. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids 77, 332-337 (2012).
38. Fagny, M. et al. Exploring the occurrence of classic selective sweeps in humans using whole-genome sequencing data sets. Mol. Biol. Evol. 31, 1850-1868 (2014).
39. Kemper, K. E., Saxton, S. J., Bolormaa, S., Hayes, B. J. & Goddard, M. E. Selection for complex traits leaves little or no classic signatures of selection. BMC Genomics 15, 246 (2014).
40. Perry, J. R. et al. DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. Hum. Mol. Genet. 23, 2490-2497 (2014).
41. Tung, J. Y. et al. Efficient replication of over 180 genetic associations with self-reported medical data. PLoS One 6, e23473 (2011).
42. Dastani, Z. et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-Analysis of 45,891 individuals. PLoS. Genet. 8, e1002607 (2012).
43. Anderson, E. L. et al. Anti-mullerian hormone is not associated with cardiometabolic risk factors in adolescent females. PLoS One 8, e64510 (2013).
44. Grossman, S. R. et al. Identifying recent adaptations in large-scale genomic data. Cell 152, 703-713 (2013).
45. Berg, J. J. & Coop, G. A population genetic signal of polygenic adaptation. PLoS. Genet. 10, e1004412 (2014).
46. 1000 Genomes Project Consortium et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).